Trial Profile
Single-Arm Phase II Combination Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 06 Jan 2023 Status changed from active, no longer recruiting to completed.
- 26 Sep 2022 Planned End Date changed from 1 Aug 2022 to 1 Dec 2022.
- 29 Mar 2021 Planned End Date changed from 1 Mar 2022 to 1 Aug 2022.